Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 429,690 shares of the biotechnology company's stock after acquiring an additional 30,000 shares during the period. DekaBank Deutsche Girozentrale owned 0.14% of Exelixis worth $11,028,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new position in shares of Exelixis during the 3rd quarter valued at approximately $30,000. Park Place Capital Corp purchased a new position in shares of Exelixis in the 2nd quarter worth $45,000. GAMMA Investing LLC increased its holdings in shares of Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company's stock worth $45,000 after buying an additional 1,041 shares during the last quarter. EntryPoint Capital LLC raised its position in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,746 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in shares of Exelixis in the 3rd quarter valued at about $74,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Stock Up 2.3 %

Shares of Exelixis stock traded up $0.76 during mid-day trading on Thursday, hitting $33.20. The stock had a trading volume of 4,421,822 shares, compared to its average volume of 2,058,661. The firm has a market cap of $9.47 billion, a P/E ratio of 27.97, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54. The firm has a 50-day moving average of $26.81 and a two-hundred day moving average of $24.15. Exelixis, Inc. has a 12-month low of $19.20 and a 12-month high of $33.60.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. The company had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Sell-side analysts expect that Exelixis, Inc. will post 1.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EXEL. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. Guggenheim boosted their price objective on shares of Exelixis from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday. Truist Financial lifted their price target on shares of Exelixis from $33.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday. TD Cowen increased their price objective on shares of Exelixis from $27.00 to $34.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Finally, BMO Capital Markets boosted their target price on Exelixis from $29.00 to $36.00 and gave the company an "outperform" rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $31.44.

Insider Activity

In other news, Director Maria C. Freire sold 8,250 shares of the business's stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total transaction of $219,120.00. Following the completion of the transaction, the director now directly owns 91,007 shares of the company's stock, valued at approximately $2,417,145.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Maria C. Freire sold 8,250 shares of Exelixis stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total transaction of $219,120.00. Following the completion of the sale, the director now directly owns 91,007 shares of the company's stock, valued at approximately $2,417,145.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 125,000 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at $19,622,479.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 352,858 shares of company stock worth $9,349,879. Corporate insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.